Inclusion Criteria:

- Patient must have biopsy proven high-grade (severe)dysplasia, carcinoma-in-situ or
early stage adenocarcinoma

- Patient may have received prior therapy; e.g.Nd-YAG laser, radiation therapy or
chemotherapy. At least one-month must have elapsed between prior treatments and PDT

- Tumors (HGD/CIS or early adenocarcinoma) can be primary or recurrent, Stage 0 or I
N0M (any)

- Patients must have no contraindication to endoscopy

- Male or female patients must be 18 years old or older. Female patients must not be
pregnant and must be practicing a medically acceptable form of birth control or be
sterile or post-menopausal. A Pregnancy test is required and must be negative.

- Patients must sign an Informed Consent according to FDA guidelines and be acceptable
to the RPCI IRB

- Patients must have a Karnofsky status 50 or above.

- Patients with early invasive adenocarcinoma will be included only if they are
considered poor surgical risks, have failed or refused XRT/chemo, or refused surgery.

- If the patients has had cancer other than non-melanoma skin cancer, their treating
physician must deem them disease-free.

Exclusion Criteria:

- Patients with tumors of grade greater than T-1.

- Porphyria or hypersensitivity to porphyrin or porphyrin-like compounds

- WBC<4000; platelet count<100,000; prothrombin times 1.5 times above upper normal
limit.

- Patients with impaired renal and/or hepatic function (total serum bilirubin > 3.0
mg/d, serum creatinine>3 mg%, alkaline phosphatase (hepatic) or SGOT> 3 times the
upper normal limit.

- Patients on concurrent chemotherapy or radiation therapy will be excluded as well as
those having received prior treatment for the esophageal cancer within 4 weeks of
enrollment.